Literature DB >> 18475466

Induction of circulating phospholipase A(2) by intravenous administration of recombinant human tumour necrosis factor.

W Pruzanski1, M L Sherman, D W Kufe, P Vadas.   

Abstract

We have examined the effects of intravenous infusion of recombinant human tumour necrosis factor (rh-TNF) on serum activity of phospholipase A(2) (PLA(2)) in patients with malignancies. Nine patients received a 24 h continuous intravenous infusion ranging from 1.0 x 10(5) U/m(2) to 3.0 x 10(5) U/m(2); 14 patients received a 5 day continuous intravenous infusion ranging from 0.5 x 10(5) U/m(2)/day to 3.0 10(5) U/m(2)/day. Twenty one of 23 patients responded with marked increases in serum PLA(2) activity that were detectable 3 h after the beginning of the rh-TNF infusion and reached maximum levels at 18 h with a mean increase of 16.2-fold. In patients receiving a 5 day rh-TNF infusion, the highest levels of PLA(2) were observed after the first day of infusion. Serum PLA(2) activity declined continuously to 2.9-fold above baseline at the end of the infusion. A significant correlation was noted between the dose of infused rh-TNF and the maximum increase in PLA(2) activity. To our knowledge, this is the first time that an association between intravenous TNF administration and induction of circulating PLA(2) in man has been established.

Entities:  

Year:  1992        PMID: 18475466      PMCID: PMC2365345          DOI: 10.1155/S0962935192000358

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  30 in total

Review 1.  Secretory synovial fluid phospholipase A2 and its role in the pathogenesis of inflammation in arthritis.

Authors:  W Pruzanski; P Vadas
Journal:  J Rheumatol       Date:  1988-11       Impact factor: 4.666

Review 2.  The role of tumor necrosis factor and interleukin 1 in the immunoinflammatory response.

Authors:  J W Larrick; S L Kunkel
Journal:  Pharm Res       Date:  1988-03       Impact factor: 4.200

3.  Chronic TNF infusion causes anorexia but not accelerated nitrogen loss.

Authors:  H R Michie; M L Sherman; D R Spriggs; J Rounds; M Christie; D W Wilmore
Journal:  Ann Surg       Date:  1989-01       Impact factor: 12.969

4.  Pathogenesis of hypotension in septic shock: correlation of circulating phospholipase A2 levels with circulatory collapse.

Authors:  P Vadas; W Pruzanski; E Stefanski; B Sternby; R Mustard; J Bohnen; I Fraser; V Farewell; C Bombardier
Journal:  Crit Care Med       Date:  1988-01       Impact factor: 7.598

5.  Involvement of phospholipase A2 activation in tumour cell killing by tumour necrosis factor.

Authors:  M L Neale; R A Fiera; N Matthews
Journal:  Immunology       Date:  1988-05       Impact factor: 7.397

Review 6.  Cachectin: a hormone that triggers acute shock and chronic cachexia.

Authors:  K J Tracey; S F Lowry; A Cerami
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

7.  Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study.

Authors:  D R Spriggs; M L Sherman; H Michie; K A Arthur; K Imamura; D Wilmore; E Frei; D W Kufe
Journal:  J Natl Cancer Inst       Date:  1988-09-07       Impact factor: 13.506

8.  Effect of tumor necrosis factor on GTP binding and GTPase activity in HL-60 and L929 cells.

Authors:  K Imamura; M L Sherman; D Spriggs; D Kufe
Journal:  J Biol Chem       Date:  1988-07-25       Impact factor: 5.157

9.  Edema-inducing activity of phospholipase A2 purified from human synovial fluid and inhibition by aristolochic acid.

Authors:  B S Vishwanath; A A Fawzy; R C Franson
Journal:  Inflammation       Date:  1988-12       Impact factor: 4.092

10.  Reduced tumour necrosis factor-induced cytotoxicity by inhibitors of the arachidonic acid metabolism.

Authors:  P Suffys; R Beyaert; F Van Roy; W Fiers
Journal:  Biochem Biophys Res Commun       Date:  1987-12-16       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.